| Dennis William Treubig, DPT | |
|
2800 Marcus Ave, New Hyde Park, NY 11042-1008 | |
| (516) 622-6161 | |
| Not Available |
| Full Name | Dennis William Treubig |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 19 Years |
| Location | 2800 Marcus Ave, New Hyde Park, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003830969 | NPI | - | NPPES |
| 028095-1 | Other | NY | LICENSE NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 028095-1 (New York) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Evolve Physical Therapy, Pllc | 2668644527 | 13 |
News Archive
A study conducted by Hiroshima University researchers found that using Ultraviolet C light with a wavelength of 222 nanometers which is safer to use around humans effectively kills SARS-CoV-2 - the first research in the world to prove its efficacy against the virus that causes COVID-19.
Threshold Pharmaceuticals, Inc., today reported financial results for the first quarter ended March 31, 2010.
In this Daily Beast opinion piece, Sarah Brown, an adjunct professor at the Institute for Global Health Innovations at Imperial College in London and global patron of the White Ribbon Alliance for Safe Motherhood, and Sabaratnam Arulkumaran, head of obstetrics and gynecology and deputy head of clinical sciences at St. George's University of London, highlight the Global Health Policy Summit scheduled to take place in London on Wednesday.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
› Verified 5 days ago
| Provider Name | Sports Physical Therapy Occupational Therapy And Rehabilitation Servic |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1770540593 PECOS PAC ID: 0446140446 Enrollment ID: O20040315001603 |
News Archive
A study conducted by Hiroshima University researchers found that using Ultraviolet C light with a wavelength of 222 nanometers which is safer to use around humans effectively kills SARS-CoV-2 - the first research in the world to prove its efficacy against the virus that causes COVID-19.
Threshold Pharmaceuticals, Inc., today reported financial results for the first quarter ended March 31, 2010.
In this Daily Beast opinion piece, Sarah Brown, an adjunct professor at the Institute for Global Health Innovations at Imperial College in London and global patron of the White Ribbon Alliance for Safe Motherhood, and Sabaratnam Arulkumaran, head of obstetrics and gynecology and deputy head of clinical sciences at St. George's University of London, highlight the Global Health Policy Summit scheduled to take place in London on Wednesday.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
› Verified 5 days ago
| Provider Name | Prohealth Care Associates Llp |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1275596280 PECOS PAC ID: 4486544186 Enrollment ID: O20040317000468 |
News Archive
A study conducted by Hiroshima University researchers found that using Ultraviolet C light with a wavelength of 222 nanometers which is safer to use around humans effectively kills SARS-CoV-2 - the first research in the world to prove its efficacy against the virus that causes COVID-19.
Threshold Pharmaceuticals, Inc., today reported financial results for the first quarter ended March 31, 2010.
In this Daily Beast opinion piece, Sarah Brown, an adjunct professor at the Institute for Global Health Innovations at Imperial College in London and global patron of the White Ribbon Alliance for Safe Motherhood, and Sabaratnam Arulkumaran, head of obstetrics and gynecology and deputy head of clinical sciences at St. George's University of London, highlight the Global Health Policy Summit scheduled to take place in London on Wednesday.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
› Verified 5 days ago
| Provider Name | Evolve Physical Therapy, Pllc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1215216288 PECOS PAC ID: 2668644527 Enrollment ID: O20111019000152 |
News Archive
A study conducted by Hiroshima University researchers found that using Ultraviolet C light with a wavelength of 222 nanometers which is safer to use around humans effectively kills SARS-CoV-2 - the first research in the world to prove its efficacy against the virus that causes COVID-19.
Threshold Pharmaceuticals, Inc., today reported financial results for the first quarter ended March 31, 2010.
In this Daily Beast opinion piece, Sarah Brown, an adjunct professor at the Institute for Global Health Innovations at Imperial College in London and global patron of the White Ribbon Alliance for Safe Motherhood, and Sabaratnam Arulkumaran, head of obstetrics and gynecology and deputy head of clinical sciences at St. George's University of London, highlight the Global Health Policy Summit scheduled to take place in London on Wednesday.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
› Verified 5 days ago
| Provider Name | Babiec & Roth Physical Therapy Pllc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1457931214 PECOS PAC ID: 4688073364 Enrollment ID: O20210601000032 |
News Archive
A study conducted by Hiroshima University researchers found that using Ultraviolet C light with a wavelength of 222 nanometers which is safer to use around humans effectively kills SARS-CoV-2 - the first research in the world to prove its efficacy against the virus that causes COVID-19.
Threshold Pharmaceuticals, Inc., today reported financial results for the first quarter ended March 31, 2010.
In this Daily Beast opinion piece, Sarah Brown, an adjunct professor at the Institute for Global Health Innovations at Imperial College in London and global patron of the White Ribbon Alliance for Safe Motherhood, and Sabaratnam Arulkumaran, head of obstetrics and gynecology and deputy head of clinical sciences at St. George's University of London, highlight the Global Health Policy Summit scheduled to take place in London on Wednesday.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dennis William Treubig, DPT 16 Baldwin St, Farmingdale, NY 11735-4333 Ph: () - | Dennis William Treubig, DPT 2800 Marcus Ave, New Hyde Park, NY 11042-1008 Ph: (516) 622-6161 |
News Archive
A study conducted by Hiroshima University researchers found that using Ultraviolet C light with a wavelength of 222 nanometers which is safer to use around humans effectively kills SARS-CoV-2 - the first research in the world to prove its efficacy against the virus that causes COVID-19.
Threshold Pharmaceuticals, Inc., today reported financial results for the first quarter ended March 31, 2010.
In this Daily Beast opinion piece, Sarah Brown, an adjunct professor at the Institute for Global Health Innovations at Imperial College in London and global patron of the White Ribbon Alliance for Safe Motherhood, and Sabaratnam Arulkumaran, head of obstetrics and gynecology and deputy head of clinical sciences at St. George's University of London, highlight the Global Health Policy Summit scheduled to take place in London on Wednesday.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
› Verified 5 days ago
Mohamed Mansour, PHYSICAL THERAPIST Physical Therapist Medicare: Medicare Enrolled Practice Location: 5 Dakota Dr Ste 200, New Hyde Park, NY 11042 Phone: 718-281-8521 | |
Bob Chang, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1991 Marcus Ave, New Hyde Park, NY 11042 Phone: 516-467-8730 | |
Dr. Anish Philip Mathew, PT, MPT (NEURO), DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1605 Hillside Ave, New Hyde Park, NY 11040 Phone: 516-616-0942 Fax: 516-616-0943 | |
Sebi Ann Varghese, D.P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 18 Evans St, New Hyde Park, NY 11040 Phone: 516-458-9171 | |
Saichellam S Nattu, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1929 New Hyde Park Rd, New Hyde Park, NY 11040 Phone: 516-233-2534 | |
Maritess Parrel Sagrado, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1979 Marcus Ave Ste 204, New Hyde Park, NY 11042 Phone: 516-327-4681 |